@misc{10481/79037,
year = {2022},
month = {11},
url = {https://hdl.handle.net/10481/79037},
abstract = {Sclerostin is most recognized for its role in controlling bone formation; however, it is also
expressed in the heart, aorta, coronary, and peripheral arteries. Human studies have associated high
circulating sclerostin levels with the presence of different cardiovascular diseases (CVD), surrogate
CVD markers, and a high risk of cardiovascular events in some populations. However, this is still a
matter of scientific debate, as the results have been very heterogeneous among studies. In the present
review, the association between serum sclerostin levels and CVD and/or cardiovascular mortality
was analyzed. For this purpose, a scoping review was performed in which articles measuring serum
sclerostin levels and cardiovascular risk in patients were selected. Eleven articles answered the
research question; of these articles, 8/11 evaluated the association between sclerostin and CVD, of
which 4/8 found a positive association, 2/8 found a negative association, and 2/8 found no association
between variables. Five (5/11) of the articles included in the study evaluated cardiovascular
mortality, of which 3/5 found a positive association, 1/5 found a negative association, and 1/5
found no association between variables. In conclusion, we did not find sufficient results to be able to
demonstrate an association between elevated sclerostin levels and the development of CVD and/or
cardiovascular mortality in the general population due to heterogeneity in the results. However, there
seems to be a tendency to consider increased sclerostin levels as a risk factor for both the development
of cardiovascular events and cardiovascular mortality in specific populations. Further studies in this
field will help to solve some of the inconsistencies found during this scoping review and allow for the
future use of sclerostin measurement as a strategy in the prevention and diagnosis of CVD and/or
cardiovascular mortality.},
organization = {Instituto de Salud Carlos III
European Commission	PI18-00803	
PI21/01069	
PI18-01235	
CD20/00022},
organization = {European Commission},
organization = {Junta de Andalucia	PI-0268-2019	
RH-0069-2021},
organization = {Instituto de Salud Carlos III},
organization = {University of Granada	FI19/00118},
organization = {European Commission	8110},
publisher = {MDPI},
keywords = {Biomarkers},
keywords = {Cardiovascular disease},
keywords = {Cardiovascular mortality},
keywords = {Cardiovascular risk},
keywords = {Sclerostin},
title = {Exploring the Role of Sclerostin as a Biomarker of Cardiovascular Disease and Mortality: A Scoping Review},
doi = {10.3390/ijerph192315981},
author = {Sanabria de la Torre, Raquel and González Salvatierra, Sheila and García Fontana, Cristina and Andújar Vera, Francisco Luis and García Fontana, Beatriz and Muñoz Torres, Manuel Eduardo and Riquelme Gallego, Blanca},
}